Mirion Technologies (MIR) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Mirion published the results on October 27, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Mirion reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted EPS, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• From 2026 Mirion's Adjusted EPS no longer adds back stock-based compensation. The year-ago Adjusted EPS of $0.12 excluded $4.4 million of it, so the two figures are on different bases.
• Q3 2026 revenue includes $41.4 million from recent acquisitions, mainly Paragon Energy Solutions (bought December 1, 2025) and Certrec, both in the Nuclear & Safety segment.

Source: Mirion Q3 2026 results, October 27, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Mirion splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Mirion's Nuclear & Safety revenue was $194 million in Q3 2026, up 34% from $145 million in Q3 2025, 70% of total revenue.
• Mirion's Medical revenue was $83.8 million in Q3 2026, up 7% from $78.5 million in Q3 2025, 30% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

The release also guides Adjusted EBITDA of about $285 million to $292 million (previously $285 million to $300 million), a margin of about 24.7% to 25.2%, and Adjusted Free Cash Flow of about $170 million to $185 million.

In its Q3 2026 release, Mirion said:

“Revenue growth of approximately 24%-25%; includes foreign exchange rate and acquisition-related impacts (previously 22.0%-24.0%).”

“Organic Revenue growth of approximately 7%-8% (previously 5.0%-7.0%).”

“Adjusted EPS of approximately $0.50-$0.54 per share (previously $0.48 - $0.55 per share).”

Source: Mirion Q3 2026 release, Oct 27, 2026.

This is the company's own guidance as of Oct 27, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the MIR forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Revenue in millions and GAAP diluted EPS, each as first reported in that quarter's release. The Q4 2025 release states GAAP net earnings per share of $0.07 for the quarter. Adjusted EPS is left out because its definition changed in 2026.

We do not hold a confirmed date for Mirion's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 27, 2026

Mirion sells radiation detection, measurement, analysis and monitoring products and services in two segments. In Q3 2026 Nuclear & Safety, which serves nuclear power plants, defense and research labs, had revenue of $194.0 million against $144.6 million, and Medical, covering nuclear medicine, radiation therapy QA, occupational dosimetry and diagnostic imaging, had $83.8 million against $78.5 million. Total revenue rose 24.5% to $277.8 million. (Mirion Q3 2026 release, Oct 27, 2026; Mirion Form 10-Q, Q3 2026, Oct 28, 2026)

Acquisitions supplied most of the growth: Nuclear & Safety gained $41.4 million of revenue from recent acquisitions, plus $6.9 million of organic volume growth and $2.3 million of price increases, less $1.2 million of currency effects. Paragon Energy Solutions, which Mirion bought on December 1, 2025 for $588.6 million of gross consideration, supplies engineered solutions for large nuclear plants and small modular reactors in the United States. Mirion put organic revenue growth at 6.5%. (Mirion Form 10-Q, Q3 2026, Oct 28, 2026; Mirion Q3 2026 release, Oct 27, 2026)

Medical revenue grew on $3.5 million of organic volume growth, mainly in cameras, and $1.8 million of price increases. By type, product revenue was $213.5 million and service revenue $64.3 million. (Mirion Form 10-Q, Q3 2026, Oct 28, 2026; Mirion Q3 2026 release, Oct 27, 2026)

Mirion says it has a presence in over 98% of commercial nuclear power plants worldwide and that about 80% of its nuclear power-related revenue comes from reactors already operating. No single customer accounted for more than 10% of revenue. Remaining performance obligations were $1,248.2 million at September 30, 2026, up from $1,104.3 million at the end of 2025. (Mirion Q3 2026 release, Oct 27, 2026; Mirion Form 10-Q, Q3 2026, Oct 28, 2026)

Mirion earned $0.03 a diluted share on a GAAP basis in Q3 2026 and $0.12 of Adjusted EPS. The biggest adjustment is $29.4 million of amortization of acquired intangibles, which rose from $25.7 million after the Paragon and Certrec deals; non-operating expenses of $3.1 million were also added back, less an $8.4 million tax effect. (Mirion Q3 2026 release, Oct 27, 2026)

Adjusted EPS was flat at $0.12 because the 2026 figure now carries stock-based compensation, which was $7.1 million in the quarter, while the 2025 figure added back $4.4 million of it. Adjusted EBITDA, which still excludes it, rose 23.7% to $64.8 million. (Mirion Q3 2026 release, Oct 27, 2026)

Diluted weighted average shares were 272.889 million, including 30.321 million potential shares from convertible debt, against 255.662 million a year earlier. Mirion spent $96.8 million buying stock for treasury in the first nine months of 2026, and treasury shares rose to 9,408,713. (Mirion Q3 2026 release, Oct 27, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Mirion gives full-year guidance in its release and revised it in Q3: 2026 revenue growth of about 24% to 25%, organic revenue growth of 7% to 8%, Adjusted EBITDA of $285 million to $292 million (previously up to $300 million), and Adjusted EPS of $0.50 to $0.54, against $0.48 to $0.55 before. (Mirion Q3 2026 release, Oct 27, 2026)

Chief executive Thomas Logan said Mirion expects mid-to-high teens organic revenue growth in the fourth quarter and net leverage of about 2.6x by year end. Adjusted Free Cash Flow guidance rose to $170 million to $185 million. (Mirion Q3 2026 release, Oct 27, 2026)

A consensus figure is the average of the models published by the analysts who cover Mirion, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Mirion's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning MIR is on is MIR a buy or a sell?, what analysts expect next is on the MIR forecast, and what the company does is on the Mirion Technologies (MIR) stock page.

Every number on this page can be traced to a document Mirion published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.